{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:04:55Z","timestamp":1784189095264,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Arcutis Biotherapeutics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40257-026-01035-0","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:04:54Z","timestamp":1778641494000},"page":"803-818","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Considerations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness Consortium"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1481-9554","authenticated-orcid":false,"given":"Michael","family":"Payette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-1024","authenticated-orcid":false,"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melodie","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Boreham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6703-5537","authenticated-orcid":false,"given":"Lucinda","family":"Whitney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1005-5221","authenticated-orcid":false,"given":"John","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8725-5767","authenticated-orcid":false,"given":"Sandra","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehla","family":"Admani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0137-9624","authenticated-orcid":false,"given":"Jeannette","family":"Jakus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7015-3817","authenticated-orcid":false,"given":"Tiffany","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4886-4567","authenticated-orcid":false,"given":"John G.","family":"Zampella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa S.","family":"Seal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Bohnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-7263","authenticated-orcid":false,"given":"Jennifer","family":"Cather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"1035_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2340\/00015555-1885","volume":"95","author":"K Meeuwis","year":"2015","unstructured":"Meeuwis K, Hullu J, IntHout J, Hendriks I, Sparreboom E, Massuger L, et al. Genital Psoriasis Awareness Program: physical and psychological care for patients with genital psoriasis. Acta Derm Venereol. 2015;95:211\u20136. https:\/\/doi.org\/10.2340\/00015555-1885.","journal-title":"Acta Derm Venereol"},{"key":"1035_CR2","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jaad.2015.02.1127","volume":"72","author":"C Ryan","year":"2015","unstructured":"Ryan C, Sadlier M, De Vol E, Patel M, Lloyd AA, Day A, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015;72:978\u201383. https:\/\/doi.org\/10.1016\/j.jaad.2015.02.1127.","journal-title":"J Am Acad Dermatol"},{"key":"1035_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s13555-017-0204-3","volume":"7","author":"JC Cather","year":"2017","unstructured":"Cather JC, Ryan C, Meeuwis K, Potts Bleakman AJ, Naegeli AN, Edson-Heredia E, et al. Patients\u2019 perspectives on the impact of genital psoriasis: a qualitative study. Dermatol Ther (Heidelb). 2017;7:447\u201361. https:\/\/doi.org\/10.1007\/s13555-017-0204-3.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1035_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/PTT.S169389","volume":"8","author":"E Yang","year":"2018","unstructured":"Yang E, Beck K, Sanchez I, Koo J, Liao W. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl). 2018;8:41\u20137. https:\/\/doi.org\/10.2147\/PTT.S169389.","journal-title":"Psoriasis (Auckl)"},{"key":"1035_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/24755303231160683","volume":"8","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Gondo GC, Bell S, Echeverr\u00eda C, Schmitt-Egenolf M, Skov L, et al. Psoriasis involving special areas is associated with worse quality of life, depression, and limitations in the ability to participate in social roles and activities. J Psoriasis Psoriatic Arthritis. 2023;8:100\u20136. https:\/\/doi.org\/10.1177\/24755303231160683.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"1035_CR6","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1402a52","volume":"14","author":"D Orsini","year":"2024","unstructured":"Orsini D, Malagoli P, Balato A, Bianchi L, Brianti P, Buononato D, et al. Bimekizumab for the treatment of plaque psoriasis with involvement of genitalia: a 16-week multicenter real-world experience: IL PSO (Italian Landscape Psoriasis). Dermatol Pract Concept. 2024;14:e2024052. https:\/\/doi.org\/10.5826\/dpc.1402a52.","journal-title":"Dermatol Pract Concept"},{"key":"1035_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/ajd.14227","volume":"65","author":"M Wu","year":"2024","unstructured":"Wu M, Fischer G. Adult genital psoriasis: an updated review for clinicians. Australas J Dermatol. 2024;65:e1-12. https:\/\/doi.org\/10.1111\/ajd.14227.","journal-title":"Australas J Dermatol"},{"key":"1035_CR8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s13555-018-0257-y","volume":"8","author":"KM Beck","year":"2018","unstructured":"Beck KM, Yang EJ, Sanchez IM, Liao W. Treatment of genital psoriasis: a systematic review. Dermatol Ther (Heidelb). 2018;8:509\u201325. https:\/\/doi.org\/10.1007\/s13555-018-0257-y.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1035_CR9","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1111\/ddg.14437","volume":"19","author":"P Staubach","year":"2021","unstructured":"Staubach P, Plavic\u2010Radeka N, Peveling\u2010Oberhag A, Sohn A, Zimmer S, Weyer\u2010Elberich V, et al. High prevalence and little awareness in patients with chronic inflammatory skin diseases and genital involvement. JDDG. 2021;19:1443\u20138. https:\/\/doi.org\/10.1111\/ddg.14437.","journal-title":"JDDG"},{"key":"1035_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000338858","volume":"224","author":"KAP Meeuwis","year":"2012","unstructured":"Meeuwis KAP, van de Kerkhof PCM, Massuger LFAG, de Hullu JA, van Rossum MM. Patients\u2019 experience of psoriasis in the genital area. Dermatology. 2012;224:271\u20136. https:\/\/doi.org\/10.1159\/000338858.","journal-title":"Dermatology"},{"key":"1035_CR11","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s13555-021-00620-x","volume":"11","author":"S Gupta","year":"2021","unstructured":"Gupta S, Garbarini S, Nazareth T, Khilfeh I, Costantino H, Kaplan D. Characterizing outcomes and unmet needs among patients in the United States with mild-to-moderate plaque psoriasis using prescription topicals. Dermatol Ther (Heidelb). 2021;11:2057\u201375. https:\/\/doi.org\/10.1007\/s13555-021-00620-x.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"1035_CR12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/bjd.17147","volume":"180","author":"M Larsabal","year":"2019","unstructured":"Larsabal M, Ly S, Sbidian E, Moyal-Barracco M, Dauendorffer J-N, Dupin N, et al. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br J Dermatol. 2019;180:647\u201356. https:\/\/doi.org\/10.1111\/bjd.17147.","journal-title":"Br J Dermatol"},{"key":"1035_CR13","unstructured":"Arcutis Biotherapeutics. Data on file. 2021."},{"key":"1035_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/jvc2.70043","volume":"4","author":"J Cather","year":"2025","unstructured":"Cather J, Young M, Boreham M, Admani S, Bhutani T, Foster E, et al. Genital psoriasis: shining liight on this hidden disease. JEADV Clin. Pract. 2025;4:719\u201331. https:\/\/doi.org\/10.1002\/jvc2.70043.","journal-title":"JEADV Clin Pract."},{"key":"1035_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s13555-021-00536-6","volume":"11","author":"JJ Hong","year":"2021","unstructured":"Hong JJ, Mosca ML, Hadeler EK, Brownstone ND, Bhutani T, Liao WJ. Genital and inverse\/intertriginous psoriasis: an updated review of therapies and recommendations for practical management. Dermatol Ther (Heidelb). 2021;11:833\u201344. https:\/\/doi.org\/10.1007\/s13555-021-00536-6.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"1035_CR16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1701-2163(16)34304-3","volume":"31","author":"EN Van","year":"2009","unstructured":"Van EN, Allen L, Giesbrecht E, Jamieson MA, Kives S, Morris M, et al. Pediatric vulvovaginal disorders: a diagnostic approach and review of the literature. J Obstet Gynaecol Canada. 2009;31:850\u201362. https:\/\/doi.org\/10.1016\/S1701-2163(16)34304-3.","journal-title":"J Obstet Gynaecol Canada."},{"key":"1035_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/LGT.0b013e31824b9e5e","volume":"16","author":"S Kapila","year":"2012","unstructured":"Kapila S, Bradford J, Fischer G. Vulvar psoriasis in adults and children. J Low Genit Tract Dis. 2012;16:364\u201371. https:\/\/doi.org\/10.1097\/LGT.0b013e31824b9e5e.","journal-title":"J Low Genit Tract Dis"},{"key":"1035_CR18","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.bpobgyn.2014.07.004","volume":"28","author":"RC Simpson","year":"2014","unstructured":"Simpson RC, Murphy R. Paediatric vulvar disease. Best Pract Res Clin Obstet Gynaecol. 2014;28:1028\u201341. https:\/\/doi.org\/10.1016\/j.bpobgyn.2014.07.004.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"1035_CR19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s13555-020-00390-y","volume":"10","author":"A Pinter","year":"2020","unstructured":"Pinter A, Mielke N, Malisiewicz B, Kaufmann R, K\u00f6nig A. Management of paediatric psoriasis by paediatricians: a questionnaire-based survey. Dermatol Ther (Heidelb). 2020;10:671\u201380. https:\/\/doi.org\/10.1007\/s13555-020-00390-y.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"1035_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40272-015-0137-1","volume":"17","author":"IMGJ Bronckers","year":"2015","unstructured":"Bronckers IMGJ, Paller AS, van Geel MJ, van de Kerkhof PCM, Seyger MMB. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Pediatr Drugs. 2015;17:373\u201384. https:\/\/doi.org\/10.1007\/s40272-015-0137-1.","journal-title":"Pediatr Drugs"},{"key":"1035_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40272-023-00592-9","volume":"26","author":"E Lie","year":"2024","unstructured":"Lie E, Choi M, Wang S-P, Eichenfield LF. Topical management of pediatric psoriasis: a review of new developments and existing therapies. Pediatr Drugs. 2024;26:9\u201318. https:\/\/doi.org\/10.1007\/s40272-023-00592-9.","journal-title":"Pediatr Drugs"},{"key":"1035_CR22","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1080\/09546634.2022.2059051","volume":"33","author":"AA Hebert","year":"2022","unstructured":"Hebert AA, Browning J, Kwong PC, Duarte AM, Price HN, Siegfried E. Managing pediatric psoriasis: update on treatments and challenges: a review. J Dermatolog Treat. 2022;33:2433\u201342. https:\/\/doi.org\/10.1080\/09546634.2022.2059051.","journal-title":"J Dermatolog Treat"},{"key":"1035_CR23","first-page":"S10","volume":"18","author":"D DiRuggiero","year":"2025","unstructured":"DiRuggiero D, Agopian J, Baker A, Blair A, Brunner M, Dinallo A, et al. Recommendations for topical corticosteroid use and the role of alternative, advanced targeted topical treatments in the treatment of chronic inflammatory skin diseases. J Clin Aesthet Dermatol. 2025;18:S10\u20133.","journal-title":"J Clin Aesthet Dermatol."},{"key":"1035_CR24","first-page":"S16","volume":"18","author":"D DiRuggiero","year":"2025","unstructured":"DiRuggiero D, DiRuggiero M. Beyond skin deep: the systemic impact of topical corticosteroids in dermatology. J Clin Aesthet Dermatol. 2025;18:S16-20.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1035_CR25","doi-asserted-by":"publisher","DOI":"10.5070\/D331164978","author":"J Burshtein","year":"2025","unstructured":"Burshtein J, Chovatiya R, Golant A, Zakria D, Shah M, Lio P, et al. Risks of topical corticosteroid therapy and role for advanced targeted topical treatments for inflammatory skin diseases: an expert consensus panel. Dermatol Online J. 2025. https:\/\/doi.org\/10.5070\/D331164978.","journal-title":"Dermatol Online J"},{"key":"1035_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, et al. Joint American Academy of Dermatology: National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82:161\u2013201. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.049.","journal-title":"J Am Acad Dermatol"},{"key":"1035_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","volume":"84","author":"CA Elmets","year":"2021","unstructured":"Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84:432\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.087.","journal-title":"J Am Acad Dermatol"},{"key":"1035_CR28","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/j.1365-2133.2007.08201.x","volume":"157","author":"YH Liao","year":"2007","unstructured":"Liao YH, Chiu HC, Tseng YS, Tsai TF. Comparison of cutaneous tolerance and efficacy of calcitriol 3\u00a0\u03bcg\u00a0g\u22121 ointment and tacrolimus 0\u00b73\u00a0mg\u00a0g\u22121 ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol. 2007;157:1005\u201312. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08201.x.","journal-title":"Br J Dermatol"},{"key":"1035_CR29","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","volume":"385","author":"MG Lebwohl","year":"2021","unstructured":"Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385:2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2103629.","journal-title":"N Engl J Med"},{"key":"1035_CR30","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaad.2022.06.1171","volume":"87","author":"B Strober","year":"2022","unstructured":"Strober B, Stein Gold L, Bissonnette R, Armstrong AW, Kircik L, Tyring SK, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING\u00a03 trial. J Am Acad Dermatol. 2022;87:800\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2022.06.1171.","journal-title":"J Am Acad Dermatol"},{"key":"1035_CR31","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2022.15632","volume":"328","author":"MG Lebwohl","year":"2022","unstructured":"Lebwohl MG, Kircik LH, Moore AY, Stein Gold L, Draelos ZD, Gooderham MJ, et al. Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials. JAMA. 2022;328:1073\u201384. https:\/\/doi.org\/10.1001\/jama.2022.15632.","journal-title":"JAMA"},{"key":"1035_CR32","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jaad.2023.10.020","volume":"90","author":"JF Merola","year":"2024","unstructured":"Merola JF, Parish LC, Guenther L, Lynde C, Lacour J-P, Staubach P, et al. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024;90:485\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2023.10.020.","journal-title":"J Am Acad Dermatol"},{"key":"1035_CR33","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.jaad.2023.11.068","volume":"90","author":"L Fiorillo","year":"2024","unstructured":"Fiorillo L, Becker E, de Lucas R, Belloni-Fortina A, Armesto S, Elewski B, et al. Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial. J Am Acad Dermatol. 2024;90:1232\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2023.11.068.","journal-title":"J Am Acad Dermatol"},{"key":"1035_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RGB, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37\u201349. https:\/\/doi.org\/10.1016\/j.jaad.2015.03.049.","journal-title":"J Am Acad Dermatol"},{"key":"1035_CR35","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.jsxm.2018.09.004","volume":"15","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch G, Foley P, Ryan C, Cather JC, Meeuwis KA, Burge R, et al. Ixekizumab improved patient-reported genital psoriasis symptoms and impact of symptoms on sexual activity vs placebo in a randomized, double-blind study. J Sex Med. 2018;15:1645\u201352. https:\/\/doi.org\/10.1016\/j.jsxm.2018.09.004.","journal-title":"J Sex Med"},{"key":"1035_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2319304","volume":"35","author":"D Orsini","year":"2024","unstructured":"Orsini D, Caldarola G, Dattola A, Campione E, Bernardini N, Frascione P, et al. Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER-study). J Dermatolog Treat. 2024;35:2319304. https:\/\/doi.org\/10.1080\/09546634.2024.2319304.","journal-title":"J Dermatolog Treat"},{"key":"1035_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2393376","volume":"35","author":"D Orsini","year":"2024","unstructured":"Orsini D, Megna M, Assorgi C, Balato A, Balestri R, Bernardini N, et al. Efficacy and safety of bimekizumab in elderly patients: real-world multicenter retrospective study: IL PSO (Italian Landscape Psoriasis). J Dermatolog Treat. 2024;35:2393376. https:\/\/doi.org\/10.1080\/09546634.2024.2393376.","journal-title":"J Dermatolog Treat"},{"key":"1035_CR38","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/bmj.311.7001.376","volume":"311","author":"J Jones","year":"1995","unstructured":"Jones J, Hunter D. Qualitative research: consensus methods for medical and health services research. BMJ. 1995;311:376\u201380. https:\/\/doi.org\/10.1136\/bmj.311.7001.376.","journal-title":"BMJ"},{"key":"1035_CR39","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1097\/OLQ.0b013e3180ca8f3a","volume":"34","author":"R Teague","year":"2007","unstructured":"Teague R, Newton D, Fairley CK, Hocking J, Pitts M, Bradshaw C, et al. The differing views of male and female patients toward chaperones for genital examinations in a sexual health setting. Sex Transm Dis. 2007;34:1004\u20137. https:\/\/doi.org\/10.1097\/OLQ.0b013e3180ca8f3a.","journal-title":"Sex Transm Dis"},{"key":"1035_CR40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/jamadermatol.2018.3442","volume":"155","author":"A Molina-Leyva","year":"2019","unstructured":"Molina-Leyva A, Salvador-Rodriguez L, Martinez-Lopez A, Ruiz-Carrascosa JC, Arias-Santiago S. Association between psoriasis and sexual and erectile dysfunction in epidemiologic studies: a systematic review. JAMA Dermatol. 2019;155:98\u2013106. https:\/\/doi.org\/10.1001\/jamadermatol.2018.3442.","journal-title":"JAMA Dermatol"},{"key":"1035_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0655","volume":"158","author":"AS Paller","year":"2022","unstructured":"Paller AS, Seyger MMB, Magari\u00f1os GA, Pinter A, Cather JC, Rodriguez-Capriles C, et al. Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis. JAMA Dermatol. 2022;158:533. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0655.","journal-title":"JAMA Dermatol"},{"key":"1035_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/pde.14870","volume":"39","author":"HY Sun","year":"2022","unstructured":"Sun HY, Phan K, Paller AS, Sebaratnam DF. Biologics for pediatric psoriasis: a systematic review and meta\u2010analysis. Pediatr Dermatol. 2022;39:42\u20138. https:\/\/doi.org\/10.1111\/pde.14870.","journal-title":"Pediatr Dermatol"},{"key":"1035_CR43","doi-asserted-by":"publisher","first-page":"280-7.e1","DOI":"10.1016\/j.jaad.2015.09.056","volume":"74","author":"AS Paller","year":"2016","unstructured":"Paller AS, Siegfried EC, Pariser DM, Rice KC, Trivedi M, Iles J, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74:280-7.e1-3. https:\/\/doi.org\/10.1016\/j.jaad.2015.09.056.","journal-title":"J Am Acad Dermatol"},{"key":"1035_CR44","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1136","volume":"161","author":"MJ Gooderham","year":"2025","unstructured":"Gooderham MJ, Alonso-Llamazares J, Bagel J, Bhatia N, Bukhalo M, DuBois J, et al. Roflumilast foam, 0.3%, for psoriasis of the scalp and body. JAMA Dermatol. 2025;161:698. https:\/\/doi.org\/10.1001\/jamadermatol.2025.1136.","journal-title":"JAMA Dermatol"},{"key":"1035_CR45","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40257-022-00741-9","volume":"24","author":"AW Thurston","year":"2023","unstructured":"Thurston AW, Osborne DW, Snyder S, Higham RC, Burnett P, Berk DR. Pharmacokinetics of roflumilast cream in chronic plaque psoriasis: data from phase I to phase III studies. Am J Clin Dermatol. 2023;24:315\u201324. https:\/\/doi.org\/10.1007\/s40257-022-00741-9.","journal-title":"Am J Clin Dermatol"},{"key":"1035_CR46","unstructured":"Organon and Co. A phase 3 study of tapinarof for the treatment of plaque psoriasis in pediatric subjects. ClinicalTrials.gov identifier: NCT05172726. 2021. https:\/\/clinicaltrials.gov\/study\/NCT05172726. Accessed 20 Aug 2025."},{"key":"1035_CR47","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jaad.2024.03.030","volume":"91","author":"L Stein Gold","year":"2024","unstructured":"Stein Gold L, Adam DN, Albrecht L, Alonso-Llamazares J, Ferris LK, Gooderham MJ, et al. Long-term safety and effectiveness of Roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial. J Am Acad Dermatol. 2024;91:273\u201380. https:\/\/doi.org\/10.1016\/j.jaad.2024.03.030.","journal-title":"J Am Acad Dermatol"},{"key":"1035_CR48","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2220849","volume":"34","author":"D Orsini","year":"2023","unstructured":"Orsini D, Gargiulo L, Ibba L, Cascio Ingurgio R, Valenti M, Perugini C, et al. Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers. J Dermatolog Treat. 2023;34:2220849. https:\/\/doi.org\/10.1080\/09546634.2023.2220849.","journal-title":"J Dermatolog Treat"},{"key":"1035_CR49","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/1346-8138.17115","volume":"51","author":"M Valenti","year":"2024","unstructured":"Valenti M, Gargiulo L, Ibba L, Cortese A, Toso F, Orsini D, et al. Effectiveness of ixekizumab for the treatment of moderate\u2010to\u2010severe plaque psoriasis with involvement of difficult\u2010to\u2010treat areas: a 52\u2010week multicenter retrospective study. J Dermatol. 2024;51:839\u201343. https:\/\/doi.org\/10.1111\/1346-8138.17115.","journal-title":"J Dermatol"},{"key":"1035_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jdv.20187","volume":"39","author":"C Bonifati","year":"2025","unstructured":"Bonifati C, Lembo S, Richetta AG, Romanelli M, Satolli F, Corazza M, et al. Effectiveness of guselkumab in patients with facial and\/or genital psoriasis: interim analysis results at week 12 from the GULLIVER study. J Eur Acad Dermatol Venereol. 2025;39:7\u201314. https:\/\/doi.org\/10.1111\/jdv.20187.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1035_CR51","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.16736","volume":"179","author":"C Ryan","year":"2018","unstructured":"Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179:844\u201352. https:\/\/doi.org\/10.1111\/bjd.16736.","journal-title":"Br J Dermatol"},{"key":"1035_CR52","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/jdv.16181","volume":"34","author":"JF Merola","year":"2020","unstructured":"Merola JF, Ghislain P-D, Dauendorffer JN, Potts Bleakman A, Brnabic AJM, Burge R, et al. Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate\u2010to\u2010severe genital psoriasis. J Eur Acad Dermatol Venereol. 2020;34:1257\u201362. https:\/\/doi.org\/10.1111\/jdv.16181.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1035_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14993","volume":"34","author":"G Calianno","year":"2021","unstructured":"Calianno G, Esposito M, Fidanza R, Palmieri M, Fargnoli MC. Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: a 24\u2010week real\u2010life experience. Dermatol Ther. 2021;34:e14993. https:\/\/doi.org\/10.1111\/dth.14993.","journal-title":"Dermatol Ther"},{"key":"1035_CR54","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/GME.0000000000001728","volume":"28","author":"NA Phillips","year":"2021","unstructured":"Phillips NA, Bachmann GA. The genitourinary syndrome of menopause. Menopause. 2021;28:579\u201388. https:\/\/doi.org\/10.1097\/GME.0000000000001728.","journal-title":"Menopause"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01035-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01035-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01035-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:21:59Z","timestamp":1784186519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01035-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1035"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01035-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MP, TB, MY, MB, LW, JK, SJ, SA, JJ, TM, JGZ, and JC received honoraria for participation in the Genital Psoriasis Wellness Consortium. MG, RK, and CR received honoraria for reviewing the final consensus statements. MP has served as a consultant for AbbVie, Amgen, Apogee Therapeutics, Arcutis, BMS, Boehringer Ingelheim, Botanix, Castle Biosciences, Dermavant (Organon), Disc Medicine, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Nielsen BioSciences, Novartis, ONVIV, Ortho Dermatologics, Oruka, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharmaceuticals, Takeda, UCB, and VeraDermics; as a speaker for AbbVie, Amgen, Arcutis, BMS, Botanix, Dermavant (Organon), Galderma, Incyte, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharmaceuticals, and UCB; and an investigator for AbbVie, Cara Therapeutics, CorEvitas Atopic Dermatitis Registry, CorEvitas Psoriasis Registry, Dermavant (Organon), Dermira, Incyte, Lilly, Mindera, Novartis, Oruka, and Takeda. TB has received research funding from Amgen, Castle Biosciences, CorEvitas, Novartis, Pfizer, and Regeneron. She has served as an advisor for AbbVie, Arcutis, ASLAN Pharmaceuticals, BMS, Boehringer Ingelheim, Dermavant, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Pfizer, Novartis, Sanofi, Sun Pharma, Takeda, and UCB. She is a speaker for AbbVie, Amgen, Arcutis, BMS, Dermavant, Galderma, Janssen, LEO Pharma, Lilly, Ortho Dermatologics, Sanofi, and UCB. MY has received consulting fees from Arcutis, Dermavant, and Lilly; personal fees or honoraria for speakers bureaus from Arcutis and Dermavant; and serves as a board member for the Society of Dermatology Nurse Practitioners, which receives grants from Arcutis, Dermavant, and Lilly. MB has received consulting fees, personal fees, or honoraria for lectures, presentations, speakers bureaus, or educational events, and support for attending meetings and\/or travel from Arcutis. LW reports no additional conflicts of interest. JK has received honoraria from AbbVie, Arcutis, AbbVie, Amgen, Castle Biosciences, Celltrion, Galderma, Janssen, Lilly, Sun Pharma, Regeneron\/Sanofi, Pfizer, and UCB for being a speaker and\/or an advisor. RF has received honoraria for lectures, presentations, speakers bureaus, educational events, or advisory boards from Almirall, Dermavant, and Sanofi. SJ has received honoraria for lectures, presentations, speakers bureaus, educational events, or advisory boards, investigator fees, or grants\/research funding from AbbVie, Amgen, Arcutis, Arkansas College of Osteopathic Medicine, BioMetrix, BMS, Cara Therapeutics, Castle Biosciences, Concert Pharmaceuticals, Dermavant, Evidera, Galderma, Incyte, Innovaderm, Janssen, Kansas Foundation for Medical Care, LEO Pharma, Lilly, National Psoriasis Foundation, Nielsen BioSciences, Novartis, Regeneron, Sanofi, Takeda, TARGET Pharma, and University of Pennsylvania, and has received other financial benefit as the founder of Type IV Technologies. SA has received personal fees or honoraria for lectures, presentations, speakers bureaus, or educational events from Arcutis, LEO Pharma, Lilly, Maui Derm, Medscape, Peds 360, and the Permanente Medical Group; and support for attending meetings and\/or travel from Maui Derm and MedScape. JJ has received consulting fees, personal fees, or honoraria for lectures, presentations, speakers bureaus, educational events, or advisory boards as well as support for attending meetings and\/or travel from Arcutis; and has served as principal investigator for Amgen, Arcutis, and National Psoriasis Foundation and as a sub-investigator for Janssen. TM reports grants or contracts with payments to the University of Alabama at Birmingham from Acelyrin, BMS, ChemoCentryx, Galderma, Janssen, Lilly, and Pfizer; honoraria for consulting services from AbbVie, Arcutis, BMS, Bodewell, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Physician Education Resources (PER), and UCB; honoraria for participation on data safety monitoring boards or advisory boards from AbbVie, Arcutis, BMS, Bodewell, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, and UCB; and serves as a board member or editorial board member for the Association of Clinical Research Professionals (ACRP), the Southeastern Consortium for Dermatology, the Skin of Color Society, and the\n                      Journal of the American Academy of Dermatology\n                      . JZ has received compensation\/honoraria from Dermavant, Ferndale Pharma Group, Janssen, Merck, and the Vaseline Healing Project, and serves as chair of the American Academy of Dermatology State Society Relationship Committee and the American Academy of Dermatology LGBTQ Expert Research Group. MS, DH, and KB are employees of Arcutis Biotherapeutics, Inc. JC has received consulting fees, personal fees, or honoraria for lectures, presentations, speakers bureaus, or educational events from AbbVie, Amgen, Arcutis, Dermavant, LEO Pharma, Lilly, and Pfizer.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not required as the nature of this work did not utilize any animal or human participants.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors provided (i) substantial contributions to conception and design, or drafting the consensus statements through the modified Delphi process (JC, MY, MB, SA, TB, RF, JJ, SJ, JK, TM, MP, LW, JGZ, KB, MSS, and DH); (ii) drafting the article or revising it critically for important intellectual content; and (iii) final approval of the version to be published.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}